DEINOVE passes the first milestone of the AGIR programm and receives €1.5m from Bpifrance

• The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of several hundred strains monthly;
• Bpifrance paid €1.5m to DEINOVE as part of the first milestone payment of the AGIR Programme.

Montpellier, March 21, 2019 (6:30 pm – CET) – DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has successfully completed the first key milestone of the AGIR program – Antibiotics against Resistant Infectious Germs – which is supported by the Investments for the Future Program. This milestone triggered the payment of €1.5m.

Full PR available here